COMPASS Pathways plc (CMPS) — Company Research

COMPASS Pathways plc (NASDAQ: CMPS) is a UK-incorporated, US-listed clinical-stage biotechnology company developing COMP360, a proprietary synthetic psilocybin formulation, primarily for treatment-resistant depression (TRD), with additional indications in post-traumatic stress disorder (PTSD) and anorexia nervosa (per the FY2025 10-K, Item 1, filed 2026-03-24). For the year ended December 31, 2025 the Company reported no commercial revenue, an operating loss of -$179.0 million (per EDGAR XBRL OperatingIncomeLoss, 10-K period ending 2025-12-31), a net loss of -$287.9 million (per the FY2025 10-K, Item 7), and research and development expense of $118.4 million (per the FY2025 10-K, Item 7, filed 2026-03-24). The Company ended Q1 2026 with $466.0 million of cash and cash equivalents (per the Q1 2026 10-Q, filed 2026-05-13), funding operations into 2028 (per the FY2025 10-K, Item 7). The stock last traded at $11.81 against a 52-week range of $2.25 to $12.235 (per yfinance, pulled 2026-05-26), with Q1 2026 reported on 2026-05-13 and the 2026 Annual General Meeting scheduled for 2026-05-27. COMPASS Pathways employed 156 people as of 2025-12-31 — 49% in the US and 51% in the UK (per the FY2025 10-K, Item 1, filed 2026-03-24).

1. Company Snapshot

2. Bull Case vs Bear Case

Bull Case

• Both pivotal Phase 3 trials hit their primary endpoints. Per the FY2025 10-K (Item 1, filed 2026-03-24): the COMP005 trial (n=258) demonstrated a least-square-means treatment difference of -7.2 on MADRS for a single 25mg dose of COMP360 versus placebo at week 6, with a p-value of <0.001. The COMP006 trial (n=581) demonstrated a clinically meaningful difference of -3.8 on MADRS for two fixed 25mg doses (administered three weeks apart) versus 1mg, with a p-value of <0.001 (announced 2026-02-17 per Compass Pathways).
• FDA granted rolling NDA review and a Commissioner's National Priority Voucher (CNPV). Per Compass Pathways' announcement (2026-04-24): the FDA granted a rolling NDA submission for COMP360 in TRD and awarded the company a CNPV, which would enable an ultra-accelerated FDA review of 1–2 months following final NDA submission, while maintaining the agency's safety and efficacy standards.
• Strongly funded balance sheet — runway into 2028. Per the FY2025 10-K (Item 7, filed 2026-03-24): the Company expects that its cash, cash equivalents and short-term investments together with the proceeds from the exercise of all outstanding 2025 ADS Warrants will be sufficient to fund operating expenses and capital expenditure requirements into 2028. Per the Q1 2026 10-Q (filed 2026-05-13): cash and cash equivalents stood at $466.0 million at 2026-03-31, up from $149.6 million at 2025-12-31, supported by $87.9 million of proceeds from ADS warrant exercises.
• NDA submission and potential 2027 launch are line-of-sight. Per the Q1 2026 earnings release (2026-05-13): the Company expects to report 26-week Part B data from COMP006 in early Q3 2026, complete its NDA submission in Q4 2026, and be "launch ready" by year-end 2026, with the CNPV potentially compressing FDA review to 1–2 months thereafter.
• Pipeline extends beyond TRD. Per the FY2025 10-K (Item 1, filed 2026-03-24): COMPASS has finalised the design of a Phase 2b/3 trial for COMP360 in PTSD, and is also pursuing studies in anorexia nervosa, broadening the long-term commercial opportunity beyond the lead TRD indication.

Bear Case

• No commercial product and a deepening accumulated deficit. Per the FY2025 10-K (Item 7, filed 2026-03-24): the Company has reported zero commercial revenue since inception, FY2025 operating loss widened to -$179.0 million (EDGAR XBRL) from -$157.1 million in FY2024, and net loss expanded to -$287.9 million in FY2025 from -$155.1 million in FY2024, taking the accumulated deficit to -$822.6 million.
• Material historical dilution to fund development. Per the FY2025 10-K (balance sheet, filed 2026-03-24): shares outstanding rose from 42.6 million at FY2022 year-end to 96.1 million at FY2025 year-end, and stood at approximately 134.9 million as of 2026-05-26 (per yfinance) — roughly a 3.2x increase over three years, with proceeds from ordinary share, pre-funded warrant and ADS warrant issuances funding the burn.
• GAAP earnings are volatile because of warrant fair-value remeasurement. Per the Q1 2026 10-Q (filed 2026-05-13): GAAP net income was +$91.2 million in Q1 2026 even though loss from operations was -$42.9 million, because a fair-value change in warrant liabilities contributed +$130.9 million of other income. Per the FY2025 10-K (Item 7) and Q3/Q4 2025 prints: Q3 2025 reported a -$137.7 million net loss versus a -$36.6 million operating loss for similar reasons, in the opposite direction.
• Psilocybin remains a Schedule I controlled substance and is novel. Per the FY2025 10-K (Item 1A, filed 2026-03-24): COMP360 contains psilocybin, which is currently a Schedule I controlled substance in the US, requiring DEA scheduling action and certified treatment-centre delivery alongside any FDA approval — adding regulatory, operational and reimbursement complexity that other oral antidepressants do not face.
• Founder/early-backer overhang and concentrated specialist ownership. Per insider transactions via yfinance and the FY2025 10-K (filed 2026-03-24): co-founders George Goldsmith and Ekaterina Malievskaia have sold material amounts of stock (including sales at $6.43 per share on 2024-10-24), and atai Life Sciences NV — a long-standing related-party investor — sold 2.66 million shares at $6.05 in September 2024. Institutional ownership is highly concentrated in specialist healthcare/biotech funds (Deep Track 9.01%, RTW 7.88%), exposing the stock to fast positioning shifts.

3. What Does COMPASS Pathways Actually Do?

COMPASS Pathways is a single-asset, clinical-stage biotechnology company. Per the FY2025 10-K (Item 1, filed 2026-03-24): its entire revenue model today is investigational — there are no commercial products and no product revenue. The reportable revenue line in the 10-K is zero in each of FY2022, FY2023, FY2024 and FY2025.

Source: the FY2025 10-K, Item 7, filed 2026-03-24.

In plain English, the company is developing COMP360 — a proprietary, GMP-grade synthetic formulation of psilocybin (the active compound in psychedelic mushrooms) — to be administered as a single or repeat dose in a supervised treatment setting alongside psychological support, for patients whose major depressive disorder has not responded to two or more standard antidepressants (so-called treatment-resistant depression, or TRD) (per the FY2025 10-K, Item 1, filed 2026-03-24). The primary efficacy measure is the Montgomery–Åsberg Depression Rating Scale (MADRS), an interviewer-administered depression severity score. The Company also has Phase 2/3 programs in PTSD and Phase 2 work in anorexia nervosa (per the FY2025 10-K, Item 1).

Geographically, COMPASS' R&D is split between the United Kingdom (London headquarters, with UK R&D tax-credit benefit) and the United States (clinical operations, New York office) (per the FY2025 10-K, Item 1 and Q1 2026 10-Q, filed 2026-05-13).

4. The Business Model

Per the FY2025 10-K (Item 1, filed 2026-03-24): COMPASS Pathways' business model is, today, a pre-commercial R&D model — drug development funded by equity issuance, ADS warrant exercises and UK R&D tax credits, with future revenue contingent on FDA (and later non-US) approval of COMP360. There is no product, no collaboration revenue and no royalty income.

The post-launch operating model the Company describes has three load-bearing elements (per the FY2025 10-K, Item 1, filed 2026-03-24). First, COMP360 must be delivered as a medically supervised treatment session — patients receive the psilocybin dose at a certified treatment centre and undergo a multi-hour session with psychological support — which means the addressable channel is specialist clinics and centres rather than retail pharmacies, and capacity ramp depends on training and certifying providers. Second, intellectual property protection rests on a portfolio around the synthetic psilocybin composition of matter and use methods, and on regulatory exclusivities (Breakthrough Therapy designation from 2018; CNPV awarded 2026-04-24). Third, manufacturing is via contract manufacturing organisations (CMOs); COMPASS does not own manufacturing facilities.

A defining feature of the financing model is the warrant capital stack. Per the Q1 2026 10-Q (filed 2026-05-13): the Company has both 2025 ADS Warrants (issued in a January 2025 underwritten offering) and pre-funded warrants/PIPE warrants outstanding; these are accounted for as liabilities at fair value, so quarterly GAAP earnings move sharply with the share price even though no cash changes hands.

5. Financial Health

5-year income trend (per the FY2025 10-K Item 7 and yfinance annual financials; FY2021 not in source data):

Per the FY2025 10-K (Item 7, filed 2026-03-24): FY2025 R&D expense of $118.4 million was essentially flat versus FY2024's $119.0 million as the COMP005 and COMP006 Phase 3 trials read out; SG&A rose to $60.6 million (FY2024: $59.2 million) as launch-preparation activities began. The wider gap between FY2025 net loss (-$287.9 million) and operating loss (-$179.0 million) versus FY2024 reflects fair-value remeasurement on warrant liabilities tied to a sharply rising share price during 2025.

Balance sheet (per the FY2025 10-K, balance sheet, filed 2026-03-24 and the Q1 2026 10-Q, filed 2026-05-13):

Per the FY2025 10-K (balance sheet, filed 2026-03-24): the FY2024-to-FY2025 movement to a stockholders' deficit reflects the FY2025 net loss of -$287.9 million partially offset by $140.4 million of capital stock issuance during the year. Accumulated deficit rose to -$822.6 million at FY2025 year-end. Total debt of $35.0 million is small relative to cash and is comprised primarily of operating-lease liabilities (per the FY2025 10-K, Notes to the consolidated financial statements).

Quarterly trend, last 5 quarters (per yfinance quarterly financials and the Q1 2026 earnings release dated 2026-05-13):

Note on EPS arithmetic in Q1 2026: GAAP net income of +$91.2 million is positive, but the diluted EPS calculation (per the Q1 2026 10-Q, filed 2026-05-13) reverses the +$130.9 million warrant fair-value gain when those warrants are dilutive, producing a numerator of -$39.7 million and a diluted EPS of -$0.30 — i.e., the GAAP net income and the diluted EPS look directionally opposite because of the warrant accounting.

6. Valuation & Market Data

Raw market data only — no commentary on cheap or expensive.

7. What Are They Building / What's Coming

Per the FY2025 10-K (Item 1, filed 2026-03-24), the Q1 2026 earnings release (2026-05-13) and named public announcements, COMPASS Pathways' near-term roadmap includes:

• COMP360 NDA in TRD — rolling submission underway, CNPV-eligible. Per Compass Pathways' announcement (2026-04-24): the FDA granted a rolling NDA submission for COMP360 in treatment-resistant depression and awarded a Commissioner's National Priority Voucher (CNPV), which would entitle COMP360 to an ultra-accelerated 1–2 month FDA review following final NDA submission while preserving the agency's safety and efficacy standards.
• 26-week COMP006 Part B data — early Q3 2026; final NDA Q4 2026. Per the Q1 2026 earnings release (2026-05-13): the Company expects to report 26-week (Part B) data from COMP006 in early Q3 2026 and to complete final NDA submission for COMP360 in Q4 2026, with launch-readiness activities targeted for year-end 2026.
• PTSD — Phase 2b/3 design finalised. Per the FY2025 10-K (Item 1, filed 2026-03-24): the Company has finalised the design of a Phase 2b/3 clinical trial of COMP360 in PTSD, addressing trauma-related psychiatric disease and broadening the long-term opportunity beyond TRD.
• Anorexia nervosa and other indications. Per the FY2025 10-K (Item 1, filed 2026-03-24): a Phase II clinical trial of COMP360 in anorexia nervosa is underway, with additional indications under preclinical and translational evaluation.
• Commercial launch readiness. Per the FY2025 10-K (Item 1, filed 2026-03-24) and the Q1 2026 earnings release (2026-05-13): the Company is scaling commercialisation, marketing and manufacturing capability and certifying treatment-centre delivery for COMP360, in anticipation of a TRD launch following NDA approval.

8. Competitive Landscape

ANKTIVA is not the comparator here — COMPASS competes in TRD, where the most relevant approved comparator is Johnson & Johnson's Spravato (esketamine nasal spray). Peer comparison (per yfinance, pulled 2026-05-26; all figures in USD). COMPASS is the only company in the table with a fully read-out, two-trial Phase 3 psilocybin program in TRD; atai Life Sciences is the most direct psychedelic-platform peer; J&J is the incumbent in interventional psychiatry.

Note: peer market caps and revenue figures are illustrative and sourced from yfinance pulled 2026-05-26; clinical-stage peers (ATAI, GHRS, CYBN) have no commercial revenue and sales-based multiples are not meaningful. Spravato is Johnson & Johnson's interventional antidepressant (approved in 2019 for TRD in conjunction with an oral antidepressant; per the FY2025 10-K, Item 1, filed 2026-03-24). Among psychedelic-platform peers, GH Research is developing GH001 (inhaled mebufotenin/5-MeO-DMT) and Cybin is developing CYB003 (deuterated psilocybin analogue), each at earlier development stages than COMP360. No opinion on positioning is expressed here — clinical-stage peer comparison rests primarily on trial outcomes, regulatory status and capital strength rather than current financial multiples.

9. Leadership and Ownership

Per the FY2025 10-K (Item 1 and insider transaction filings via yfinance, pulled 2026-05-26): Kabir Nath is President and Chief Executive Officer; Teri Loxam is Chief Financial Officer. Company co-founders George Goldsmith and Ekaterina Malievskaia continue to be reported as beneficial owners of more than 10% of a class of security in recent insider filings (per insider_transactions via yfinance, pulled 2026-05-26). Detailed executive tenure and proxy-level biographical information beyond these roles is not disclosed in this report's source data (the Item 10 proxy section was not in the extracted 10-K text).

Top institutional shareholders as of 2026-03-31 (per yfinance institutional_holders, pulled 2026-05-26):

Per yfinance (pulled 2026-05-26): institutional ownership totals 72.99% and insider ownership totals 7.83%. Recent insider activity (per insider_transactions via yfinance, pulled 2026-05-26):

• 2026-03-26: CEO Kabir Nath received a 175,000-share stock-award grant at $0.00 per share (annual equity award).
• 2026-03-26: CFO Teri Loxam received a 75,000-share stock-award grant at $0.00 per share (annual equity award).
• 2024-10-24: Co-founder George Goldsmith sold 776,565 shares at $6.43 (approximately $4.99 million).
• 2024-10-24: Co-founder Ekaterina Malievskaia sold 1,553,130 shares at $6.43 (approximately $9.99 million).
• 2024-09-26: atai Life Sciences NV sold 2,660,000 shares at $6.05 (approximately $16.1 million).

10. Risks and Challenges

• No commercial product and history of significant losses (Financial): Per the FY2025 10-K (Item 1A, filed 2026-03-24): the Company has no products approved for commercial sale and has incurred net losses every year since inception; cumulative net losses of -$822.6 million had been recorded by 2025-12-31. FY2025 operating loss was -$179.0 million (EDGAR XBRL).
• Need for additional funding before potential approval (Financial): Per the FY2025 10-K (Item 1A, filed 2026-03-24): "we will need additional funding in the future to sufficiently finance our operations" — even though cash plus exercise of outstanding 2025 ADS Warrants is expected to fund operations into 2028, any delay in NDA approval, launch slip or trial expansion could pull that runway forward.
• Single-product dependence on COMP360 (Concentration): Per the FY2025 10-K (Item 1A, filed 2026-03-24): the Company's prospects are substantially dependent on the success of a single therapeutic candidate, COMP360, across TRD, PTSD and adjacent indications; any negative read-through from a Part B 26-week data point, FDA Advisory Committee, label or post-marketing data would materially impair the equity value.
• FDA approval is not guaranteed despite positive Phase 3 data (Regulatory): Per the FY2025 10-K (Item 1A, filed 2026-03-24): "even if we receive regulatory approval for COMP360 or any future therapeutic candidates," approval may be on a narrower label than sought, subject to REMS or other restrictions, or denied — the rolling NDA and CNPV do not guarantee approval.
• Psilocybin is a Schedule I controlled substance (Regulatory): Per the FY2025 10-K (Item 1A, filed 2026-03-24): COMP360 contains psilocybin, currently a Schedule I controlled substance under the US Controlled Substances Act; commercial launch requires DEA rescheduling action and ongoing controlled-substance regulatory compliance, with potential impacts from regulatory agency staffing cuts and policy changes.
• Therapy delivery operational complexity (Operational): Per the FY2025 10-K (Item 1, filed 2026-03-24): COMP360 must be administered in certified treatment centres with psychological support during a multi-hour supervised session — a delivery model that has no direct precedent in scaled oral antidepressants, creating execution risk on treatment-centre certification, training and reimbursement.
• Manufacturing dependence on contract manufacturers (Operational): Per the FY2025 10-K (Item 1A, filed 2026-03-24): the Company depends on third-party manufacturers for the supply of COMP360 GMP material; any disruption, delay or quality issue at a CMO could delay clinical trials or commercial launch.
• Reimbursement and post-approval promotional limits (Market & Demand): Per the FY2025 10-K (Item 1A, filed 2026-03-24): "we may be subject to limitations on how we may promote the therapeutic candidate; sales of the COMP360 psilocybin treatment may decrease significantly" if reimbursement is restricted or labelling is narrow, even after FDA approval.
• Competitive risk from Spravato and other emerging psychedelic/IO therapies (Competitive): Per the FY2025 10-K (Item 1, filed 2026-03-24): Spravato (esketamine, J&J) has been approved by the FDA for TRD since 2019, and other psychedelic and rapid-acting antidepressant developers (atai, GH Research, Cybin and others) are advancing competing programs.
• Cybersecurity and personal data risk (Cyber & Physical): Per the FY2025 10-K (Item 1C / Item 1A, filed 2026-03-24): the Company is "subject to health information privacy regulation by both the federal government and the states in which we conduct our business," and a cyberattack or data breach could expose the Company to fines, litigation and reputational harm.
• Concentrated specialist-fund ownership and warrant overhang (Concentration): Per yfinance institutional_holders (pulled 2026-05-26) and the Q1 2026 10-Q (filed 2026-05-13): institutional ownership is 72.99% with the top two holders (Deep Track 9.01%, RTW 7.88%) alone holding ~17% of the float; outstanding 2025 ADS Warrants and PIPE warrants represent a non-trivial additional dilution and earnings-volatility source if exercised or remeasured.

11. Recent Developments

Most recent first.

• 2026-05-19 — Compass participates in RBC Capital Markets Global Healthcare Conference: Management held a fireside chat at 10:00 a.m. ET on 2026-05-19 at the RBC Global Healthcare Conference, with a live audio webcast available on the Investors section of the Compass Pathways website. Source: Compass Pathways press release, 2026-05-14.
• 2026-05-17 — Buy consensus on CMPS (reported factually): Aggregated analyst coverage records a "Buy" consensus rating on CMPS as of 2026-05-17 (per public.com analyst-action summary). Reported here for completeness; ChartsView does not endorse this rating. Source: public.com analyst forecast.
• 2026-05-13 — Q1 2026 results: $466.0M cash, rolling NDA underway, NDA Q4 2026: Q1 2026 GAAP loss from operations was -$42.9 million, but GAAP net income was +$91.2 million owing to a +$130.9 million non-cash fair-value gain on warrant liabilities; diluted EPS -$0.30 (a $0.09 beat to the consensus -$0.39 estimate). Cash and cash equivalents were $466.0 million at 2026-03-31, providing runway into 2028. 26-week Part B data from COMP006 is expected in early Q3 2026 and final NDA submission in Q4 2026, with launch-readiness targeted for year-end. Source: Compass Pathways Q1 2026 8-K Exhibit 99.1.
• 2026-04-28 — HC Wainwright sets $70 price target (reported factually): HC Wainwright & Co. published a $70 price target on CMPS, reported in aggregated analyst-action coverage as the high target across the analyst universe. Reported here for completeness; ChartsView does not endorse this target. Source: public.com analyst forecast.

COMPASS Pathways' official X (Twitter) handle is @compasspathways. No additional independently link-verifiable X posts from the company, CEO or CFO within the 30-day window are included in this report's source data.

12. Key Dates Coming Up

• 2026-05-27 — 2026 Annual General Meeting of Stockholders: Held at 1:30 p.m. London / 8:30 a.m. ET at the offices of Goodwin Procter (UK) LLP, Sancroft, 10-15 Newgate Street, London EC1A 7AZ; record date for ADS holders was 2026-04-06 (per the DEF 14A proxy statement filed 2026-04-15).
• Early Q3 2026 — COMP006 26-week (Part B) data readout: Compass expects to report 26-week data from the pivotal COMP006 trial in early third quarter 2026 (per the Q1 2026 earnings release, 2026-05-13).
• Q4 2026 — Final NDA submission for COMP360 in TRD: Final NDA submission targeted for the fourth quarter of 2026, with the rolling NDA structure allowing modules to be filed as completed (per the Q1 2026 earnings release, 2026-05-13).
• Within 1–2 months of final NDA submission — Potential CNPV-accelerated FDA review: The Commissioner's National Priority Voucher awarded 2026-04-24 may enable a 1–2 month FDA review window after final NDA filing, subject to FDA's standard safety and efficacy review (per Compass Pathways, 2026-04-24).
• Q2 2026 earnings — date not disclosed in this report's source data: Q1 2026 was reported on 2026-05-13 (per the Q1 2026 8-K).

Risk Warning: This research is for information only and is not investment advice or a recommendation to buy or sell any security. CFD Risk Warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74–89% of retail investor accounts lose money when trading CFDs. Affiliate Disclosure: We may receive a commission from some links on this page at no extra cost to you. Data Disclaimer: All figures are sourced from company filings, earnings releases, and public market data as at the date above. Forward-looking statements are attributed to the company and may not be achieved. Always do your own research. Generated by ChartsView research tooling. Thesis strength measures how well the evidence in this report supports the company's stated thesis — it is NOT a buy/sell rating or price target. ChartsView is not authorised by the FCA to provide regulated investment advice.